![Rolf Einar Engstad](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Rolf Einar Engstad
Director/Board Member at Biotec BetaGlucans AS
Profile
Rolf Einar Engstad is currently the Director at Biotec BetaGlucans AS.
Previously, he worked as the Chief Scientific Officer at ArcticZymes Technologies ASA. He received his graduate and doctorate degrees from the University of Tromso.
Rolf Einar Engstad active positions
Companies | Position | Start |
---|---|---|
Biotec BetaGlucans AS
![]() Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Director/Board Member | - |
Former positions of Rolf Einar Engstad
Companies | Position | End |
---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Chief Tech/Sci/R&D Officer | - |
Training of Rolf Einar Engstad
University of Tromso | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Private companies | 1 |
---|---|
Biotec BetaGlucans AS
![]() Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Stock Market
- Insiders
- Rolf Einar Engstad